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ALT

:   alanine aminotransferase

AST

:   aspartate aminotransferase

CHD

:   coronary heart disease

COPD

:   chronic obstructive pulmonary disease

COVID‐19

:   coronavirus disease 2019

CRP

:   C‐reactive protein

CVD

:   cerebrovascular disease

DM

:   diabetes mellitus

ESR

:   erythrocyte sedimentation rate

ICU

:   intensive care unit

IQRs

:   interquartile ranges

LDH

:   lactic dehydrogenase

NLR

:   neutrophil‐to‐lymphocyte ratio

RT‐PCR

:   real‐time polymerase chain reaction

WBC

:   white blood cell count

1. INTRODUCTION {#jmv26003-sec-0010}
===============

The World Health Organization has officially announced coronavirus disease 2019 (COVID‐19) as pandemic,[^1^](#jmv26003-bib-0001){ref-type="ref"} and its death toll far exceeded Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome.[^2^](#jmv26003-bib-0002){ref-type="ref"}, [^3^](#jmv26003-bib-0003){ref-type="ref"} However, there is currently no effective treatment for this novel disease.[^4^](#jmv26003-bib-0004){ref-type="ref"}

Several unique characteristics have been found in severe COVID‐19, such as lymphopenia, old age, high C‐reactive protein (CRP) level and underlying co‐morbid diseases.[^5^](#jmv26003-bib-0005){ref-type="ref"}, [^6^](#jmv26003-bib-0006){ref-type="ref"}, [^7^](#jmv26003-bib-0007){ref-type="ref"}, [^8^](#jmv26003-bib-0008){ref-type="ref"}, [^9^](#jmv26003-bib-0009){ref-type="ref"}, [^10^](#jmv26003-bib-0010){ref-type="ref"}, [^11^](#jmv26003-bib-0011){ref-type="ref"} Significantly decreased albumin level is common in severe COVID‐19,[^7^](#jmv26003-bib-0007){ref-type="ref"}, [^12^](#jmv26003-bib-0012){ref-type="ref"} but the change in albumin does not parallel the severity of hepatocellular injury in COVID‐19.[^12^](#jmv26003-bib-0012){ref-type="ref"} This suggests that there may be mechanisms other than a hepatocellular injury that explains the profound hypoalbuminemia seen in COVID‐19. One of the possible mechanisms is the intense systemic inflammation being reported in severe COVID‐19.[^13^](#jmv26003-bib-0013){ref-type="ref"} Hypoalbuminemia is common in many inflammatory diseases because increased capillary permeability can result in the escape of albumin to the interstitial space.[^14^](#jmv26003-bib-0014){ref-type="ref"}

The role of albumin in the progression of COVID‐19 remains unknown. We hypothesized that serum albumin levels at admission might reflect the severity of systemic inflammation and thus can serve as a predictive factor for COVID‐19 outcomes. To address this question, we performed a retrospective study to compare the outcome in patients with or without hypoalbuminemia and to explore the impact of albumin in the prognosis of COVID‐19.

2. METHODS {#jmv26003-sec-0020}
==========

2.1. Study population {#jmv26003-sec-0030}
---------------------

This is a retrospective cohort study including adult patients with COVID‐19 disease hospitalized in the Third People\'s Hospital of Yichang, Hubei from 25th January to 24th March 2020. The inclusion criteria for enrollment into the study were; (1) age ≥ 18 years; (2) positive real‐time polymerase chain reaction (RT‐PCR) assay from naso‐pharyngeal swab specimens; (3) meet diagnostic criteria set out by World Health Organization for COVID‐19[^15^](#jmv26003-bib-0015){ref-type="ref"}; (4) with complete clinical data. The study was approved by the National Health Commission and the institutional board of the Third People\'s Hospital of Yichang, and complied with the Declaration of Helsinki.

2.2. Data collection and defining variables {#jmv26003-sec-0040}
-------------------------------------------

### 2.2.1. Patient characteristics {#jmv26003-sec-0050}

Data were extracted from the review of case notes and electronic medical records. Onset time was defined as the time since the development of first relevant symptoms of COVID‐19 to presentation in the hospital. Those who smoked more than 10 cigarettes/day in the past 30 days were considered as current smokers.[^16^](#jmv26003-bib-0016){ref-type="ref"} Heavy drinking was defined as long‐term habitual alcohol consumption, usually longer than 5 years, of more than 40 g/d in males and 20 g/d in females, or a history of binging on alcoholic beverages within the past 2 weeks with a converted alcohol intake \> 80 g/d.[^17^](#jmv26003-bib-0017){ref-type="ref"} The comorbidity of interest that was recorded was hypertension, diabetes mellitus (DM), coronary heart disease (CHD), cerebrovascular disease (CVD), chronic obstructive pulmonary disease (COPD), and cancer.

### 2.2.2. Laboratory data {#jmv26003-sec-0060}

All blood samples were obtained at admission and analyzed by standard methods in the laboratory. The routine hematological and biochemical tests included white blood cell count (WBC), neutrophil count, lymphocyte count, monocyte count, CRP, procalcitonin, erythrocyte sedimentation rate (ESR), d‐dimer, fibrinogen, and liver and kidney function tests. Neutrophil‐to‐lymphocyte ratio (NLR) value was measured by dividing the neutrophil count by the lymphocyte count.

### 2.2.3. Definition of hypoalbuminemia and lymphopenia {#jmv26003-sec-0070}

The normal range value of the serum albumin was 35‐55 g/L. Based on the previous research, we defined hypoalbuminemia as albumin less than 35 g/L.[^18^](#jmv26003-bib-0018){ref-type="ref"}

The normal range of lymphocyte count was (1‐4) × 10^9^/L, thus lymphopenia was defined as lymphocyte count of \<1 × 10^9^/L.

2.3. Statistical analysis {#jmv26003-sec-0080}
-------------------------

Continuous variables were expressed as means ± SD or medians with interquartile ranges (IQRs), according to whether the distribution was normal or skewed. Categorical variables were expressed as percentages. The Student *t* test (for variables normally distributed) and Mann‐Whitney *U* test (for variables non‐normally distributed) were performed. The difference between categorical variables was examined with the *χ* ^2^ test or Fisher\'s exact test as appropriate. A *P*‐value \< .05 was considered statistically significant. Pearson correlation analysis was used to analyze the relationship between albumin and inflammatory indicators. Data management and analysis were performed using R software (R version 3.6.3, R Foundation for Statistical Computing, Vienna, Austria).

3. RESULTS {#jmv26003-sec-0090}
==========

3.1. Baseline characteristics of patients {#jmv26003-sec-0100}
-----------------------------------------

A total of 299 adult patients were included in the study, 16 of them died of COVID‐19 and 283 survived. There were 160 (53.5%) males, and the average age of the cohort was 53.4 ± 16.7 years old. The median time from the onset of illness to admission was 3 days (IQR, 2‐5). Approximately one‐third of the patients had comorbidities, of which hypertension, DM, CHD, CVD, COPD, and cancer were present in 74 (24.7%), 35 (11.7%), 18 (6.0%), 13 (4.3%), 8 (2.7%) and 9 (3.0%) cases, respectively. A total of 113 patients (37.8%) had been to Wuhan before the illness. The most common symptoms on admission were fever (79.6%) and cough (74.2%), followed by increased phlegm/sputum production (45.2%) and dyspnea (14.0%). Lymphopenia was found in 127 (42.5%) and hypoalbuminemia in 106 (35.5%) patients. Forty‐six patients required intensive care unit (ICU) admission and treatment (Table [1](#jmv26003-tbl-0001){ref-type="table"}).

###### 

Baseline characteristic of the patients on admission

  Variables                              Total           Survivors       Non‐survivors   *P*
  -------------------------------------- --------------- --------------- --------------- --------
  N                                      299             283             16              
  Male (%)                               160 (53.5)      149 (52.7)      11 (68.8)       .318
  Age, y                                 53.4 ± 16.7     52.5 ± 16.6     69.2 ± 9.7      \<.001
  Onset time, median (IQR)               3 (2, 5)        3 (2, 5)        5 (2.5, 7.75)   .228
  ICU (%)                                46 (15.4)       31 (11)         15 (93.8)       \<.001
  Lymphopenia                            127 (42.5)      112 (39.6)      15 (93.8)       \<.001
  Hypoalbuminemia                        106 (35.5)      92 (32.5)       14 (87.5)       \<.001
  Current smoker (%)                     48 (16.1)       42 (14.8)       6 (37.5)        .028
  Heavy drinking (%)                     21 (7.0)        20 (7.1)        1 (6.2)         1
  Comorbidity                            99 (33.1)       85 (30)         14 (87.5)       \<.001
  Presence of at least one comorbidity   99 (33.1)       85 (30.0)       14 (87.5)       \<.001
  Hypertension (%)                       74 (24.7)       63 (22.3)       11 (68.8)       \<.001
  DM (%)                                 35 (11.7)       31 (11.0)       4 (25.0)        .103
  CHD (%)                                18 (6)          14 (4.9)        4 (25.0)        .011
  CVD (%)                                13 (4.3)        11 (3.9)        2 (12.5)        .148
  COPD (%)                               8 (2.7)         5 (1.8)         3 (18.8)        .006
  Cancer (%)                             9 (3.0)         5 (1.8)         4 (25.0)        \<.001
  Trip to Wuhan (%)                      113 (37.8)      106 (37.5)      7 (43.8)        .81
  Fever (%)                              238 (79.6)      224 (79.2)      14 (87.5)       .54
  Cough (%)                              222 (74.2)      208 (73.5)      14 (87.5)       .376
  Sputum (%)                             135 (45.2)      125 (44.2)      10 (62.5)       .24
  Dyspnea (%)                            42 (14)         32 (11.3)       10 (62.5)       \<.001
  Diarrhea (%)                           7 (2.3)         6 (2.1)         1 (6.2)         .322
  WBC, ×10^9^/L                          4.9 ± 2.4       4.8 ± 2.1       7.0 ± 5.2       .111
  Neutrophil, ×10^9^/L                   3.3 ± 2.1       3.2 ± 2         5.6 ± 3.4       .012
  Lymphocyte, ×10^9^/L                   1.2 ± 0.5       1.2 ± 0.5       0.6 ± 0.3       \<.001
  NLR                                    3.8 ± 5.8       3.3 ± 4.3       13.3 ± 14.3     .013
  Monocyte, ×10^9^/L                     0.3 ± 0.3       0.3 ± 0.2       0.5 ± 0.9       .501
  CRP, mg/L                              26.3 ± 34.6     24.7 ± 33.2     53.5 ± 47.7     .03
  Procalcitonin, μg/L                    0.2 ± 0.6       0.2 ± 0.6       0.3 ± 0.3       .245
  ESR, mm/h                              35.7 ± 25.9     35.1 ± 25.9     45.3 ± 25.7     .143
  FIB, g/L                               3.2 ± 1.0       3.2 ± 1         3.2 ± 1.3       .98
  D‐dimer, mg/L                          1.6 ± 5.4       1.3 ± 3.9       6 ± 16.1        .266
  Total bilirubin, μmol/L                11.0 ± 6.6      11.0 ± 6.7      11.0 ± 4.6      .993
  Albumin, g/L                           37.3 ± 6.3      37.6 ± 6.2      30.5 ± 4.0      \<.001
  LDH, U/L                               246.3 ± 178.4   229.1 ± 122.5   531.1 ± 487.3   .026
  ALT, U/L                               27.6 ± 21.6     27.5 ± 21.2     29.4 ± 28.5     .8
  AST, U/L                               26.1 ± 18.2     25.5 ± 18.2     35.4 ± 16.8     .037
  Creatinine, μmol/L                     74.6 ± 46.8     74.9 ± 48       70.2 ± 14.8     .326

*Note*: Continuous variables were expressed as means ± SD or medians with interquartile ranges (IQRs).

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; CVD, cerebrovascular disease; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; ICU, intensive care unit; LDH, lactic dehydrogenase; NLR, neutrophil‐to‐lymphocyte ratio; WBC, white blood cell count.
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3.2. Comparison of baseline characteristics between survivors and non‐survivors {#jmv26003-sec-0110}
-------------------------------------------------------------------------------

Table [1](#jmv26003-tbl-0001){ref-type="table"} illustrates the baseline values of variables in the whole population and the statistical comparison between survivors and non‐survivors. Compared with survivors, non‐survivors were older, had a higher prevalence of comorbidities and were more likely to have dyspnea and required moreICU management. The laboratory examination revealed higher levels of neutrophil, CRP, and LDH, while a lower level of lymphocyte in non‐survivors (*P* \< .05). Specifically, the liver function tests showed comparable aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, which were both statistically and clinically insignificant. However, the difference in albumin between the survival group and the non‐survivor group was considerable (37.6 ± 6.2 vs 30.5 ± 4.0 *P* \< .001). Gender, alcohol consumption, the time difference from the onset of symptom to admission (onset time), epidemiology history, and other symptoms were not significantly different between the two groups (*P* \> .05, no significance).

3.3. Comparison characteristics of the patient with hypoalbuminemia and normal albumin groups {#jmv26003-sec-0120}
---------------------------------------------------------------------------------------------

Table [2](#jmv26003-tbl-0002){ref-type="table"} illustrates the differences in the studied parameters between the hypoalbuminemia and the normal albumin group. Patients with hypoalbuminemia tended to be older, had longer onset time, and frequently required ICU management. In addition, patients with hypoalbuminemia had a higher mortality rate of 13.2% vs 1% in normal albumin group (*P* \< .001). The frequencies of lymphopenia, smoking status, comorbidities, increased phlegm/sputum production, and dyspnea were higher in the hypoalbuminemia group. As for the laboratory indicators, higher levels of inflammatory biomarkers (including WBC, neutrophil, NLR, CRP, ESR and procalcitonin), d‐dimer, fibrinogen, LDH, and AST were found (*P* \< .05) in hypoalbuminemia group. The other variables including gender, alcohol consumption, onset time, epidemiological history, fever and/or cough at presentation, serum creatinine, and other liver function tests were not statistically different between the two groups (*P* \> .05, no significance).

###### 

Differences in patient characteristics between hypoalbuminemia and normal albumin group

  Variables                              Hypoalbuminemia   Normal albumin   *P*
  -------------------------------------- ----------------- ---------------- --------
  N                                      106               193              
  Male (%)                               60 (56.6)         100 (51.8)       .501
  Age, y                                 62.9 ± 13.1       48.2 ± 16.1      \<.001
  Onset time, median (IQR)               4 (2, 7)          3 (2, 5)         .002
  ICU (%)                                34 (32.1)         12 (6.2)         \<.001
  Death (%)                              14 (13.2)         2 (1)            \<.001
  Lymphopenia                            60 (56.6)         67 (34.7)        \<.001
  Current smoker (%)                     25 (23.6)         23 (11.9)        .014
  Heavy drinking (%)                     10 (9.4)          11 (5.7)         .331
  Comorbidity                                                               
  Presence of at least one comorbidity   55 (51.9)         44 (22.8)        \<.001
  Hypertension (%)                       41 (38.7)         33 (17.1)        \<.001
  DM (%)                                 24 (22.6)         11 (5.7)         \<.001
  CHD (%)                                13 (12.3)         5 (2.6)          .002
  CVD (%)                                10 (9.4)          3 (1.6)          .002
  COPD (%)                               6 (5.7)           2 (1)            .025
  Cancer (%)                             8 (7.5)           1 (0.5)          .001
  Trip to Wuhan (%)                      36 (34)           77 (39.9)        .375
  Fever (%)                              88 (83)           150 (77.7)       .348
  Cough (%)                              82 (77.4)         140 (72.5)       .439
  Sputum (%)                             60 (56.6)         75 (38.9)        .005
  Dyspnea (%)                            27 (25.5)         15 (7.8)         \<.001
  Diarrhea (%)                           3 (2.8)           4 (2.1)          .702
  WBC, ×10^9^/L                          5.6 ± 3.3         4.5 ± 1.7        .003
  Neutrophil, ×10^9^/L                   4.1 ± 3           2.9 ± 1.4        \<.001
  Lymphocyte, ×10^9^/L                   1 ± 0.5           1.3 ± 0.5        \<.001
  NLR                                    6.2 ± 9           2.5 ± 1.5        \<.001
  Monocyte, ×10^9^/L                     0.4 ± 0.4         0.3 ± 0.2        .753
  CRP, mg/L                              43.9 ± 45.3       16.5 ± 21.7      \<.001
  Procalcitonin, μg/L                    0.3 ± 1           0.1 ± 0.2        .019
  ESR, mm/h                              51.3 ± 27.9       26.9 ± 20        \<.001
  FIB, g/L                               3.6 ± 1.1         3 ± 0.9          \<.001
  D‐dimer, mg/L                          3.1 ± 8.9         0.7 ± 1.2        .01
  Total bilirubin, μmol/L                11.3 ± 7.6        10.8 ± 6         .556
  Albumin, g/L                           31.1 ± 3.8        40.6 ± 4.7       \<.001
  LDH, U/L                               315.5 ± 269.6     209.1 ± 78.4     \<.001
  ALT, U/L                               27.9 ± 20.7       27.5 ± 22.1      .877
  AST, U/L                               30.1 ± 24.5       23.9 ± 13.3      .018
  Creatinine, μmol/L                     81.3 ± 62.6       71 ± 35.2        .126

*Note*: Continuous variables were expressed as means ± SD or medians with interquartile ranges (IQRs).

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; CVD, cerebrovascular disease; DM, diabetes mellitus; ESR, erythrocyte sedimentation rate; ICU, intensive care unit; LDH, lactic dehydrogenase; NLR, neutrophil‐to‐lymphocyte ratio; WBC, white blood cell count.
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3.4. Correlation analysis of serum albumin with inflammatory indicators {#jmv26003-sec-0130}
-----------------------------------------------------------------------

Pearson correlation analysis was used to explore the relationship between albumin and inflammatory indicators. Albumin level was inversely correlated with WBC (*r* = −.149, *P* = .01), NLR (*r* = −.298, *P* \< .001), CRP (*r* = −.345, *P* \< .001), and PCT (*r* = −.162, *P* = 007). Pearson linear correlation analysis scatter plot is shown in Figure [1](#jmv26003-fig-0001){ref-type="fig"}.

![Pearson linear correlation analysis scatter plot is shown. A indicated that the level of albumin and CRP were positively correlated; B indicated that the levels of albumin and NLR were positively correlated](JMV-9999-na-g001){#jmv26003-fig-0001}

3.5. Univariate and multivariate analysis for death outcome {#jmv26003-sec-0140}
-----------------------------------------------------------

To explore the risk factors of death, univariate and multivariate logistics regression was conducted. Univariate analysis revealed age, comorbidity, lymphopenia, and hypoalbuminemia as risk factors for death. However, in multivariate analysis, only the presence of at least one comorbidity (OR, 6.816; 95% CI, 1.361‐34.133), lymphopenia (OR, 13.130; 95% CI, 1.632‐105.658), and hypoalbuminemia (OR, 6.394; 95% CI, 1.315‐31.092) were found to be independent predictors of death (Table [3](#jmv26003-tbl-0003){ref-type="table"}).

###### 

Univariate and multivariate analysis of factors for risk of death (non‐survivors)

  Variables                              Univariate analysis   Multivariate analysis                                      
  -------------------------------------- --------------------- ----------------------- --------- -------- --------------- -------
  Male                                   1.979                 0.67‐5.841              0.217     1.245    0.358‐4.334     0.731
  Age                                    1.080                 1.036‐1.126             \<0.001   1.026    0.972‐1.083     0.353
  Presence of at least one comorbidity   16.306                3.627‐73.315            \<0.001   6.816    1.361‐34.133    0.020
  Lymphopenia                            22.902                2.983‐175.815           0.003     13.130   1.632‐105.658   0.016
  Hypoalbuminemia                        14.533                3.235‐65.282            \<0.001   6.394    1.315‐31.092    0.021

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

4. DISCUSSION {#jmv26003-sec-0150}
=============

The most important finding of our study is that there is an inverse relationship between the level of albumin and the risk of death in COVID‐19 patients. This retrospective study revealed that serum albumin level \<35 g/L at presentation independently increased the risk of death in COVID‐19 by at least 6‐fold.

Hypoalbuminemia in severe COVID‐19 has been repeatedly addressed in the literature,[^6^](#jmv26003-bib-0006){ref-type="ref"}, [^12^](#jmv26003-bib-0012){ref-type="ref"}, [^19^](#jmv26003-bib-0019){ref-type="ref"}, [^20^](#jmv26003-bib-0020){ref-type="ref"}, [^21^](#jmv26003-bib-0021){ref-type="ref"}, [^22^](#jmv26003-bib-0022){ref-type="ref"} but the predictive value of albumin has never been explored. In this study, we found that lower albumin levels on admission can predict the outcome of COVID‐19 independent of other known indicators such as lymphocyte count or comorbidities.[^3^](#jmv26003-bib-0003){ref-type="ref"} This result is consistent with a previous study reporting hypoalbuminemia or decline of albumin, which is associated with the severity of ARDS[^23^](#jmv26003-bib-0023){ref-type="ref"} or acute kidney injury.[^24^](#jmv26003-bib-0024){ref-type="ref"} A meta‐analysis showed that about 80.4% of patients with abnormal liver function in COVID‐19 had hypoalbuminemia, which was associated with prognosis and outcome.[^25^](#jmv26003-bib-0025){ref-type="ref"}

The mechanisms for hypoalbuminemia in COVID‐19 have not been thoroughly studied or explained. Albumin is synthesized in the liver with a serum half‐life of approximately 21 days.[^26^](#jmv26003-bib-0026){ref-type="ref"} Although ALT and AST slightly increased in COVID‐19 patients, they were not of predictive value for the outcome. However, hypoalbuminemia was seen predominantly in severe COVID‐19 cases compared with mild cases in a previous study[^12^](#jmv26003-bib-0012){ref-type="ref"} and the present study. This phenomenon cannot be explained by liver dysfunction secondary to hepatocellular dysfunction alone. Additionally, the median time from the onset of illness to admission was only 3 days, far shorter than the half‐life of serum albumin, suggesting that hypoalbuminemia was less likely to be a result of decreased albumin synthesis in severe COVID‐19.

In this study, a significant correlation was found between albumin level and inflammatory indicators (CRP, WBC, and NLR). Systemic inflammation is common in severe COVID‐19.[^13^](#jmv26003-bib-0013){ref-type="ref"} Inflammation has been shown to cause the escape of serum albumin into interstitial space due to increased capillary permeability, and eventually lead to increased volume distribution of albumin.[^14^](#jmv26003-bib-0014){ref-type="ref"} Thus, our study strongly implies that hypoalbuminemia might due to the systemic inflammation in COVID‐19.

Therapeutic efficacy of albumin in sepsis and cirrhosis demonstrates that it can act through a modulatory effect on inflammation and oxidative stress in addition to the plasma volume expansion.[^14^](#jmv26003-bib-0014){ref-type="ref"}, [^27^](#jmv26003-bib-0027){ref-type="ref"}, [^28^](#jmv26003-bib-0028){ref-type="ref"} Albumin treatment has been shown to improve oxygenation in ARDS by a meta‐analysis.[^29^](#jmv26003-bib-0029){ref-type="ref"} As there is no specific treatment for the systemic inflammation in COVID‐19 until now, an albumin treatment with low side‐effect could be a potential approach. However, the efficacy and safety of albumin in COVID‐19 requires to be verified in prospective studies as the majority of severe COVID‐19 is elderly with cardiovascular comorbidities.

Our study should be interpreted in light of some limitations. We have reported a single‐center experience and data in this retrospective study; however, the baseline factors in our study is consistent with the presently available literature and the single‐center experience may not be a limitation. We only showed the predictive value of baseline albumin level for outcome of COVID‐19, yet the changes in albumin levels during the evolution of COVID‐19 disease were not reflected in our data set, and whether or not the dynamic changes of albumin level are more predictive of mortality remains unknown. Also, at our center albumin therapy for the management of COVID‐19 has not been used, prospective trials/studies with albumin treatment may answer the question.

In conclusion, hypoalbuminemia defined as a serum albumin level of less than 35 g/L, is associated with the outcome of COVID‐19. The potential therapeutic value of albumin in COVID‐19 needs urgent further evaluation.
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